ATE488231T1 - Quinazolinone als kaliumkanalmodulatoren - Google Patents

Quinazolinone als kaliumkanalmodulatoren

Info

Publication number: ATE488231T1
Authority: AT; Austria
Prior art keywords: disorders; disease; compositions; useful; treatment
Prior art date: 2002-12-23

Application number

AT03808616T

Other languages

English (en)

Inventor

Grant Mcnaughton-Smith

James Thomas

George Amato

Original Assignee

Icagen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2003-12-23

Publication date

2010-12-15

2003-12-23 Application filed by Icagen Inc filed Critical Icagen Inc

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE488231T1 publication Critical patent/ATE488231T1/de

Links

102000004257 Potassium Channel Human genes 0.000 title abstract 3
108020001213 potassium channel Proteins 0.000 title abstract 3
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000000044 Amnesia Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010003591 Ataxia Diseases 0.000 abstract 1
208000020925 Bipolar disease Diseases 0.000 abstract 1
208000003174 Brain Neoplasms Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
208000011897 Deaf-Blind disease Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
208000008238 Muscle Spasticity Diseases 0.000 abstract 1
206010028632 Myokymia Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000032257 benign familial neonatal 1 seizures Diseases 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
230000004907 flux Effects 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000005264 motor neuron disease Diseases 0.000 abstract 1
239000004090 neuroprotective agent Substances 0.000 abstract 1
208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
229910001414 potassium ion Inorganic materials 0.000 abstract 1
208000018198 spasticity Diseases 0.000 abstract 1
206010044652 trigeminal neuralgia Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Liquid Crystal Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Plural Heterocyclic Compounds (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Compositions Of Macromolecular Compounds (AREA)

AT03808616T 2002-12-23 2003-12-23 Quinazolinone als kaliumkanalmodulatoren ATE488231T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43614502P	2002-12-23	2002-12-23
PCT/US2003/041657 WO2004058704A2 (en)	2002-12-23	2003-12-23	Quinazolinones as potassium channel modulators

Publications (1)

Publication Number	Publication Date
ATE488231T1 true ATE488231T1 (de)	2010-12-15

Family

ID=32682347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03808616T ATE488231T1 (de)	2002-12-23	2003-12-23	Quinazolinone als kaliumkanalmodulatoren

Country Status (8)

Country	Link
US (2)	US20040198724A1 (de)
EP (1)	EP1585522B1 (de)
JP (1)	JP4652816B2 (de)
AT (1)	ATE488231T1 (de)
AU (2)	AU2003303484C1 (de)
CA (1)	CA2505195C (de)
DE (1)	DE60335028D1 (de)
WO (1)	WO2004058704A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7230000B1 (en) *	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
JP2005529076A (ja)	2002-02-15	2005-09-29	サイトキネティクス・インコーポレーテッド	キナゾリノンの合成
EP1553931A4 (de)	2002-05-09	2006-08-30	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
EP1513820A4 (de)	2002-05-23	2006-09-13	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
WO2004034972A2 (en)	2002-09-30	2004-04-29	Cytokinetics, Inc.	Compounds, compositions, and methods
US20050089559A1 (en) *	2003-10-23	2005-04-28	Istvan Szelenyi	Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
GB0416730D0 (en)	2004-07-27	2004-09-01	Novartis Ag	Organic compounds
GB0507298D0 (en)	2005-04-11	2005-05-18	Novartis Ag	Organic compounds
WO2007057447A1 (en) *	2005-11-18	2007-05-24	Neurosearch A/S	Novel quinazoline derivatives and their medical use
US7960436B2 (en) *	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) *	2006-08-18	2008-02-21	Valeant Pharmaceuticals North America	Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) *	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en) *	2006-08-23	2011-09-29	Valeant Pharmaceuticals Int	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) *	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) *	2006-11-28	2009-11-11	威朗国际制药公司	作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
WO2008142140A2 (en) *	2007-05-23	2008-11-27	Neurosearch A/S	Novel 2,3-diamino-quinazolinone derivatives and their medical use
US8367684B2 (en) *	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) *	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) *	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8809346B2 (en)	2008-05-30	2014-08-19	Universite De Versailles-Saint-Quentin-En-Yvelines	ANT-ligands molecules and biological applications
US8563580B2 (en)	2008-09-23	2013-10-22	Georgetown University	Flavivirus inhibitors and methods for their use
CA2738313A1 (en) *	2008-09-23	2010-04-08	Georgetown University	Viral and fungal inhibitors
TWI504395B (zh)	2009-03-10	2015-10-21		Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) *	2009-03-12	2010-11-01	Gruenenthal Gmbh	Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (zh)	2009-03-12	2014-11-21		2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TWI475020B (zh)	2009-03-12	2015-03-01		The substituted nicotine amide as a KCNQ2 / 3 modifier
RU2595894C2 (ru)	2010-08-27	2016-08-27	Грюненталь Гмбх	Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
MX342459B (es)	2010-08-27	2016-09-29	Grünenthal Gmbh *	2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
CA2805932A1 (en)	2010-08-27	2012-03-01	Gruenenthal Gmbh	Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
CA2807886A1 (en)	2010-09-01	2012-03-08	Gruenenthal Gmbh	Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
US8609674B2 (en)	2010-11-16	2013-12-17	Abbvie Inc.	Potassium channel modulators
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
MX2022005490A (es)	2019-11-08	2022-08-10	Xenon Pharmaceuticals Inc	Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en)	2021-02-09	2024-04-16	Xenon Pharmaceuticals Inc.	Methods and uses for treating anhedonia
EP4333852A4 (de) *	2021-05-04	2025-03-26	Enalare Therapeutics Inc.	Kaliumkanalmodulatoren mit hoher leitfähigkeit, zusammensetzungen davon, verfahren zur herstellung davon und verfahren zur verwendung davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3867384A (en) *	1972-09-01	1975-02-18	Greg A Bullock	2-Amino-4(3H)-quinazolinones
US4855289A (en) *	1984-06-04	1989-08-08	Wester Per O	Combination of two active substances
FR2582514B1 (fr) *	1985-05-30	1988-02-19	Rhone Poulenc Sante	Medicaments a base d'amides, nouveaux amides et leur preparation
US5276038A (en) *	1992-06-01	1994-01-04	American Cyanamid Company	1-aryl-3-(3,4-dihydro-4-oxo-3-quinazolinyl)urea fungicidal agents
WO1994026722A1 (en) *	1993-05-12	1994-11-24	E.I. Du Pont De Nemours And Company	Fungicidal fused bicyclic pyrimidinones
US6255311B1 (en) *	1998-01-14	2001-07-03	E. I. Du Pont De Nemours And Company	Fungicidal fused bicyclic pyrimidinones
US6667300B2 (en) *	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
AU2004272104B2 (en) *	2003-09-10	2011-09-08	Icagen, Inc	Fused ring heterocycles as potassium channel modulators

2003
- 2003-12-23 AT AT03808616T patent/ATE488231T1/de not_active IP Right Cessation
- 2003-12-23 EP EP03808616A patent/EP1585522B1/de not_active Expired - Lifetime
- 2003-12-23 WO PCT/US2003/041657 patent/WO2004058704A2/en not_active Ceased
- 2003-12-23 DE DE60335028T patent/DE60335028D1/de not_active Expired - Lifetime
- 2003-12-23 AU AU2003303484A patent/AU2003303484C1/en not_active Ceased
- 2003-12-23 CA CA2505195A patent/CA2505195C/en not_active Expired - Fee Related
- 2003-12-23 US US10/746,205 patent/US20040198724A1/en not_active Abandoned
- 2003-12-23 JP JP2004562600A patent/JP4652816B2/ja not_active Expired - Fee Related
2009
- 2009-11-20 US US12/623,357 patent/US20100190746A1/en not_active Abandoned
- 2009-12-08 AU AU2009245837A patent/AU2009245837B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1585522B1 (de)	2010-11-17
AU2009245837B2 (en)	2011-12-01
WO2004058704A3 (en)	2005-07-07
CA2505195A1 (en)	2004-07-15
WO2004058704A2 (en)	2004-07-15
EP1585522A2 (de)	2005-10-19
EP1585522A4 (de)	2006-08-09
US20100190746A1 (en)	2010-07-29
AU2003303484C1 (en)	2012-06-14
DE60335028D1 (de)	2010-12-30
AU2003303484B2 (en)	2009-09-17
AU2003303484A1 (en)	2004-07-22
JP4652816B2 (ja)	2011-03-16
JP2006512379A (ja)	2006-04-13
CA2505195C (en)	2012-07-10
WO2004058704A8 (en)	2005-10-27
AU2009245837A1 (en)	2010-01-07
US20040198724A1 (en)	2004-10-07

Legal Events

Date	Code	Title	Description
2011-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE488231T1 (de)	2010-12-15	Quinazolinone als kaliumkanalmodulatoren
WO2005025293A3 (en)	2005-06-16	Fused ring heterocycles as potassium channel modulators
MX2010001824A (es)	2010-04-21	Heterociclos como moduladores de canal de potasio.
GB2390091A (en)	2003-12-31	Bisarylamines as potassium channel openers
SG157231A1 (en)	2009-12-29	Substituted p-diaminobenzene derivatives
MX2010002674A (es)	2010-03-25	Moduladores de gamma secretasa.
MX2010006379A (es)	2010-09-07	Moduladores de la secretasa gamma.
MX2010005028A (es)	2010-05-27	Moduladores de gamma secretasa.
WO2003101402A3 (en)	2004-08-26	Methods of treating cognitive dysfunction by modulating brain energy metabolism
TW200607513A (en)	2006-03-01	Certain chemical entities, compositions, and methods
GT200300219A (es)	2004-05-18	Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
GT200200039A (es)	2002-11-21	Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
ES2149888T3 (es)	2000-11-16	3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
EP2382975A3 (de)	2012-02-29	Neurogenese mittels Angiotensin-Modulation
BRPI0515528A (pt)	2008-07-29	n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central
MX368459B (es)	2019-10-03	Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
EP1007638A4 (de)	2004-12-29	Kcnq kaliumkanäle und verfahren zur deren veränderung
WO2006041871A3 (en)	2007-03-08	Apparatus and method for modulating neurochemical levels in the brain
BR0306855A (pt)	2005-04-05	Método para o tratamento de distúrbios cognitivos
MX2010001501A (es)	2010-03-10	Moduladores de gamma secretasa.
ATE489948T1 (de)	2010-12-15	Behandlung von autoimmunkrankheiten
TW200642690A (en)	2006-12-16	Composition for treating central nervous system disorders
MXPA05004266A (es)	2005-11-23	Cicloalquilamidas y sus usos terapeuticos como antiepileptico y anticonvulsivo.
AU2003211040A8 (en)	2003-09-09	The eaat2 promoter and uses thereof
EP1469730A4 (de)	2006-02-01	Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit